Gene

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024

AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer. These studies were presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which is being held April 5-10, 2024 in San Diego, California.

Key Points: 
  • Alectinib is an ALK-inhibitor commonly used to treat patients with ALK rearrangements such as EML4-ALK positive NSCLCs.
  • This research suggests that REQORSA may be an effective treatment in patients progressing on alectinib.
  • The study found that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect.
  • Study findings suggest that NPRL2 gene therapy induces anti-tumor activity against KRAS/STK11mt tumors through dendritic cell-mediated antigen presentation and cytotoxic immune cell activation.

International Weed Genomics Consortium Celebrates Three Years of Achievements

Retrieved on: 
Tuesday, April 9, 2024

WESTMINSTER, Colo., April 9, 2024 /PRNewswire-PRWeb/ -- Since its founding in April, 2021, the International Weed Genomics Consortium (IWGC) has been steadily advancing weed science via collaboration. These advancements include weed species genome sequencing, assembly, and annotation that are accessible via the IWGC weed species website, WeedPedia, and other collaborative databases. Additionally, IWGC offers multiple conferences and training opportunities to share its findings with others each year.

Key Points: 
  • Since its founding in April, 2021, the International Weed Genomics Consortium (IWGC) has been steadily advancing weed science via collaboration.
  • These advancements include weed species genome sequencing, assembly, and annotation that are accessible via the IWGC weed species website, WeedPedia, and other collaborative databases.
  • WESTMINSTER, Colo., April 9, 2024 /PRNewswire-PRWeb/ -- Since its founding in April, 2021, the International Weed Genomics Consortium (IWGC) has been steadily advancing weed science via collaboration.
  • These advancements include weed species genome sequencing, assembly, and annotation that are accessible via the IWGC weed species website , WeedPedia , and other collaborative databases.

Dovetail Genomics Introduces Novel LinkPrep™ NGS Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024

BOSTON, April 9, 2024 /PRNewswire/ -- Dovetail Genomics today announces the debut of its LinkPrep™ NGS technology, showcasing its potential for de novo detection of structural variants and chromatin topology features in cancer. Through its innovative chromatin conformation approach, LinkPrep™ technology exhibits enhanced sensitivity in detecting translocations and intra-chromosomal rearrangements compared to conventional methods, while also identifying SNVs/InDels within a single assay. Unlike traditional Hi-C methods, LinkPrep technology offers a streamlined process, generating sequenceable libraries from initial samples in a single shift. These findings are being presented at the AACR Annual Meeting, April 5-10, in San Diego, Calif.

Key Points: 
  • Unlike traditional Hi-C methods, LinkPrep technology offers a streamlined process, generating sequenceable libraries from initial samples in a single shift.
  • These findings are being presented at the AACR Annual Meeting, April 5-10, in San Diego, Calif.
  • This will improve the discovery and annotation of novel drivers and mechanisms of cancer.
  • Currently undergoing late-stage validation, Dovetail Genomics is actively seeking strategic partnerships to conduct further studies demonstrating its clinical utility across specific cancer indications.

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Retrieved on: 
Monday, April 8, 2024

BURLINGTON, N.C., April 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to advancing cancer research and patient care on a global scale. The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market.

Key Points: 
  • The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market.
  • "Our portfolio expansion enhances our integrated services to empower our partners with the solutions and support they need to advance their development programs and make a lasting difference in patients' lives."
  • Labcorp recently announced the commercial availability of Labcorp Plasma Detect, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) MRD solution for research and investigational use.
  • Labcorp's deep scientific expertise and comprehensive solutions include specialized pre-clinical discovery, biomarker and companion diagnostics (CDx) development and post-commercialization capabilities.

Flowers may be more ancient than dinosaurs – but scientists can’t agree on when they evolved

Retrieved on: 
Tuesday, April 9, 2024

Including more than 350,000 known species, they dominate the ecological system, shape food webs and play a vital role in oxygen production.

Key Points: 
  • Including more than 350,000 known species, they dominate the ecological system, shape food webs and play a vital role in oxygen production.
  • Plus, many of them are valuable commercial crops – think of roses, grains and tomatoes.
  • A step change in research is shaking up the way scientists think about plants: they are far more complex and more like us than you might imagine.
  • But not all scientists agree it is an angiosperm, due to the different definitions of flower organs.
  • This is the largest known amber-preserved fossil flower, measuring about 3cm across and about three times as large as most floral fossils, showing beautiful details of this ancient flower.

Jurassic or Cretaceous?

  • The timing of flowers’ evolution is still a matter of debate between scientists, but most scientists are in one of two camps: Jurassic or Cretaceous.
  • Analyses using molecular data (DNA or protein sequences) suggest flowers could be much older than the fossil record shows – a Jurassic (145 million years ago) or even Triassic origin (201 million years ago).

Deciphering the past by molecular data

  • One technique scientists use to determine the timing of evolutionary events is the “molecular clock”.
  • This concept originated from the understanding that genetic mutations tend to accumulate at a constant rate across both time and species.
  • To construct a molecular clock, researchers analyse gene segments that have been conserved throughout a species’ evolution.

Piecing the puzzle together

  • Scientists examine fossil plants and observe the gradual changes in structures such as leaves, flowers and seeds over time.
  • Comparing their anatomy allows researchers to identify similarities and differences between extinct and still-living species, or species in different clades.
  • Biological traits which appear similar may be a result of convergent evolution, indicating changes in characteristics for environmental adaptation, rather than genetic similarity.

Mathematical approach can also help

  • There is also a mathematical approach to estimating the age of angiosperms – for instance, using the Bayesian Brownian Bridge (BBB) method.
  • This statistical model is a scientific formula that uses the distribution of fossils through time to estimate the age of a group.
  • By using the BBB method, an international research team found that the origin of angiosperms supports a pre-Cretaceous hypothesis.


Ruolin Wu does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Body armour made from silk is being developed – but this apparently cutting-edge idea is centuries old

Retrieved on: 
Tuesday, April 9, 2024

The researchers modified the genes of silkworms to make them produce spider silk instead of their own silk.

Key Points: 
  • The researchers modified the genes of silkworms to make them produce spider silk instead of their own silk.
  • Harnessing the properties of spider silk has been a longstanding aim because the material is as strong as steel, yet also highly elastic.
  • However, the idea of using silk to make bulletproof vests is not a new idea.
  • Five years later, Dr Goodfellow published further observations in “Notes on the Impenetrability of Silk to Bullets” in a journal called The Southern California Practioneer.
  • Using Goodfellow’s findings, the Catholic priest Casimir Zeglen (1869–1927) would later invent a silk bulletproof vest.
  • But the potential for silk as ballistic body armour had been recognised more than two centuries earlier, by Leibniz.
  • Instead, he thought silk was the most promising material for a bulletproof fabric due to being lightweight, flexible, and strong.
  • His idea for silk bulletproof clothing therefore did not get off the drawing board.


Lloyd Strickland does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Orphan designation: Nirogacestat Treatment of soft tissue sarcoma, 17/10/2019 Positive

Retrieved on: 
Tuesday, April 9, 2024

Orphan designation: Nirogacestat Treatment of soft tissue sarcoma, 17/10/2019 Positive

Key Points: 


Orphan designation: Nirogacestat Treatment of soft tissue sarcoma, 17/10/2019 Positive

Orphan designation: Allogeneic cultured postnatal thymus-derived tissue Treatment of CHARGE syndrome, 26/02/2019 Positive

Retrieved on: 
Tuesday, April 9, 2024

Orphan designation: Allogeneic cultured postnatal thymus-derived tissue Treatment of CHARGE syndrome, 26/02/2019 Positive

Key Points: 


Orphan designation: Allogeneic cultured postnatal thymus-derived tissue Treatment of CHARGE syndrome, 26/02/2019 Positive

Orphan designation: Adeno-associated viral vector containing modified U1 snRNA Treatment of Duchenne muscular dystrophy, 08/10/2009 Positive

Retrieved on: 
Tuesday, April 9, 2024

Orphan designation: Adeno-associated viral vector containing modified U1 snRNA Treatment of Duchenne muscular dystrophy, 08/10/2009 Positive

Key Points: 


Orphan designation: Adeno-associated viral vector containing modified U1 snRNA Treatment of Duchenne muscular dystrophy, 08/10/2009 Positive

Orphan designation: Genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor for the treatment of ovarian cancer Treatment of ovarian cancer, 29/04/2014 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024

Orphan designation: Genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor for the treatment of ovarian cancer Treatment of ovarian cancer, 29/04/2014 Withdrawn

Key Points: 


Orphan designation: Genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor for the treatment of ovarian cancer Treatment of ovarian cancer, 29/04/2014 Withdrawn